Russian pharmaceutical company AKRIKHIN announces the financial results for the first half of the year 2013 prepared in accordance with the Russian Accounting Standards (RAS).

The Company's revenue for the six months of the year 2013 has increased by 21% compared with the same period of the last year and totalled 3.4 billion rubles.

The growth of gross profit has also shown positive dynamics. During the report period, AKRIKHIN's gross profit has increased by 20.17% against the same period in 2012 and totalled 1.9 billion rubles. The net profit increase relative to the first half of the previous year was 13.54% and amounted to 65.6 million rubles.

Over the six months of the year 2013 AKRIKHIN has released 3 new products. These are products of key therapeutic areas: genecology, neurology and urology. AKRIKHIN continues implementing its investment program for the development and modernization of the production facilities, covering the period 2010-2016, with a total investment of 960 million rubles. Since the launch of the investment program until June 2013 as part of the investment program AKRIKHIN has already invested in the modernization of its industrial complex 500.3 million rubles, of which 73.5 million rubles in the first half of the year 2013. In addition, the Company continues implementing cooperation projects. In July 2013 AKRIKHIN expanded cooperation with MSD and will manufacture under contract 11 MSD products for the domestic market.